An optimal treatment for pediatric Graves' disease is radioiodine.
BACKGROUND
Antithyroid medications, surgery, and radioactive iodine have been used for more than five decades for the treatment of hyperthyroidism due to Graves' disease in children, adolescents, and adults. Despite the widespread use of these different approaches, controversy still exists relative to the merits of each treatment, especially regarding the use of radioactive iodine.


OBJECTIVE
The objective of the study was to address the risk and benefits of (131)I therapy, as compared with other treatment approaches. POSITION: Long-term, spontaneous remission of Graves' disease occurs in less than 30% of children. Thus, the majority of children with Graves' disease will need definitive, curative therapy. There is little evidence that use of antithyroid medications beyond 1 or 2 yr increases the likelihood of spontaneous, long-term remission. Although the use of antithyroid medications is standard practice, the use of antithyroid medications involves definite risks. When used at sufficient doses, radioactive iodine is an effective cure for Graves' disease and is associated with few acute side effects. Potential long-term adverse side effects, including thyroid cancer and genetic damage, have yet to be observed in individuals treated as children or adolescents with (131)I.


CONCLUSIONS
Properly administered, radioactive iodine remains an ideal form of treatment for Graves' disease in the pediatric population. Because of the increased risk of thyroid cancer associated with low-dose thyroid irradiation in children, larger, rather than smaller, doses of (131)I should be given.
Rivkees
Scott A
SA
Yale Pediatric Thyroid Center, Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut 06520, USA. Scott.Rivkees@Yale.edu
Dinauer
Catherine
C
D002648:Child; D006111:Graves Disease / Q000188:drug therapy / Q000532:radiotherapy* / Q000601:surgery; D006801:Humans; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*; D018570:Risk Assessment
D007457:Iodine Radioisotopes